 |
|
|
| |
SAFETY OF OMBITASVIR/PARITAPREVIR/RITONAVIR PLUS DASABUVIR FOR TREATING HCV GT1 INFECTION IN PATIENTS WITH SEVERE RENAL IMPAIRMENT OR END-STAGE RENAL DISEASE: THE RUBY-I STUDY
|
| |
| |
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
AASLD/2014: The Pharmacokinetics and Safety of the Direct Acting Antiviral Regimen of ABT-450/r, Ombitasvir with/without Dasabuvir in Subjects with Mild, Moderate and Severe Renal Impairment Compared to Subjects with Normal Renal Function - (11/14/14)
Paul J Pockros, K Rajender Reddy, Parvez S Mantry, Eric Cohen, Michael Bennett, Mark S Sulkowski, David Bernstein, Thomas Podsadecki, Daniel Cohen, Nancy S Shulman, Deli Wang, Amit Khatri, Manal Abunimeh, Eric Lawitz
|
| |
|
|
|
|
|
